These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1360275)

  • 21. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
    Vassetzky YS; Alghisi GC; Gasser SM
    Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
    Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
    Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
    René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
    Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
    Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P
    Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
    Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D
    Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
    Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
    Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
    Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
    Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistance mediated by P-glycoproteins.
    Schinkel AH; Borst P
    Semin Cancer Biol; 1991 Aug; 2(4):213-26. PubMed ID: 1680493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.
    Vanhoefer U; Müller MR; Hilger RA; Lindtner B; Klaassen U; Schleucher N; Rustum YM; Seeber S; Harstrick A
    Br J Cancer; 1999 Dec; 81(8):1304-10. PubMed ID: 10604726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of resistance to topoisomerases poisons.
    Prost S
    Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.